| DOR BioPharma, Inc., a biopharmaceutical company, engages in the research and development of oral therapeutic products intended for areas of unmet medical needs and biodefense vaccines in the United States and internationally. It operates through two segments, BioTherapeutics and BioDefense. The BioTherapeutics segment develops orBec, an orally administered corticosteroid that exerts a potent and local anti-inflammatory effect in the mucosal tissue of the gastrointestinal tract; Oraprine, an oral suspension of azathioprine; and LPE and PLP systems for delivery of water-insoluble drugs. The BioDefense segment offers RiVax, ricin toxin vaccine, a heat stable toxin that is isolated and purified from the bean of the castor plant; and BT-VACC, the Botulinum toxin, a poisonous natural substance that causes acute, symmetric, and descending flaccid paralysis due to its action on peripheral cholinergic nerves. The company was founded in 1987 and is headquartered in Miami, Florida. |
